9 01, 2025

TAmiRNA ‘2024 In Review’

2025-01-09T14:05:02+01:00January 9th, 2025|biomarker, Biomarker Discovery, biomarkers, CE-IVD, congress, EVscale, exosomes, extracellular vesicle, hepatomiR kit, Illumina NewSeq2000, ISO 13485, liquid biopsies, Liver disease, microRNA, microRNA services, microRNAs, NGS, PCR testing service, quality, sequencing, small RNA-sequencing, smallRNA, test service|Comments Off on TAmiRNA ‘2024 In Review’

2024: A Year of Growth, Innovation, and Collaboration 2024 has come to a close. We are proud to reflect on the milestones and achievements we’ve reached together with our incredible team, customers, partners, and supporters. Here’s a look back at what we accomplished this year: 👩‍🔬 Team Expansion Welcomed 3 talented new members to our growing team. 🏥 Diagnostic Implementation Successfully rolled out our CE-IVD microRNA liver function test in 5+ clinics, advancing molecular diagnostics. ✅ Service Excellence Completed over 80 RNA service projects, achieving 100% customer satisfaction. 🛠 Bioinformatics Innovation Developed 2 new pipelines: isomiR analysis and tRNA analysis, enhancing our capabilities. 🧬 Expanded Service Offerings Added whole-transcriptome sequencing for mRNA, lncRNA, and circRNA in liquid biopsies to our service portfolio. [...]

11 12, 2024

TAmiRNA at SURGER-I Innsbruck Congress 2024

2024-12-11T14:51:38+01:00December 11th, 2024|biomarker, biomarkers, CE-IVD, congress, hepatomiR, microRNAs, small RNA-sequencing|Comments Off on TAmiRNA at SURGER-I Innsbruck Congress 2024

We are thrilled to announce that TAmiRNA will participate in the SURGER-I Innsbruck Congress on December 12–13, 2024. This premier event brings together leading experts, researchers, and practitioners to explore advancements in hepatopancreatobiliary surgery and transplantation. As a proud sponsor, we will showcase our hepatomiR® kit, the first CE-IVD microRNA biomarker for the pre-operative assessment of liver function. Attendees can find us featured in the final program and on an intermission slide during the event. We are also delighted to share that Dr. Matthias Hackl, CEO/CSO of TAmiRNA, will be attending the conference. This provides an excellent opportunity to connect and learn about our latest clinical trial data, as well as how hepatomiR® can be implemented in [...]

Go to Top